Neuronetics Receives FDA Clearance For Transcranial Magnetic Stimulation System For Depression
Executive Summary
About 50% of the 13.9 million people undergoing treatment in the US for major depressive disorder have anxious depression, which represents a large market opportunity for Neuronetics, according to an analyst.
You may also be interested in...
Neuronetics Gets Expanded Clearance For TMS Therapy System
The US FDA has cleared the NeuroStar transcranial magnetic stimulation system to treat depression in adolescents 15 through 21, making it the first and only such treatment the agency has cleared for this age group.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.